Transthyretin Amyloid Cardiomyopathy Treatment Market, By Type, By Drug Type, By Distribution Channel, By Geography

PUBLISHED: October 23, 2023

PAGES: 160 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market is estimated to be valued at US$ 1.69 Bn in 2023, and is expected to exhibit a CAGR of 31.1% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 1.69 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	31.10%	2030 Value Projection:	US$ 11.23 Bn

Figure 1. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Share (%), By Type, 2023

Transthyretin Amyloid Cardiomyopathy Treatment Market - IMG1

Transthyretin amyloid ardiomyopathy (ATTR-CM) is a rare and serious medical condition characterized by the abnormal accumulation of transthyretin protein deposits in the heart that can lead to severe cardiomyopathy and heart failure. These protein deposits disrupt the normal functioning of the heart muscle, and causes it to become stiff and less effective in pumping blood. ATTR-CM is often a progressive and life-threatening disease that primarily affects older adults, but it can also manifest in a hereditary form that affects individuals at a younger age.

The treatment of ATTR-CM is a complex and evolving field. While there is no cure for the condition, several therapeutic approaches aim to manage symptoms, slow the progression of the disease, and improve the patient's quality of life. These treatment options can include medications designed to stabilize transthyretin proteins, alleviate heart failure symptoms, and reduce the burden of amyloid deposits in the heart. In some cases, heart transplantation may be considered as a treatment option.

Market Dynamics

Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market growth is driven by ongoing research and clinical trials that are exploring innovative treatments including gene-silencing therapies and novel medications that targets the underlying causes of the disease. For instance, in November 2020, Alexion, Inc., a U.S.-based pharmaceutical company, initiated a phase 3 study that evaluates the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), and to establish its pharmacokinetic and pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM. With the entrance of new players in the market, the clinical pipeline is expected to expand further driving the growth of the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market.

Key features of the study:

This report provides an in-depth analysis of the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Detailed Segmentation:

By Type:
- Hereditary Transthyretin Amyloidosis (hATTR)
- Wild Type Transthyretin Amyloidosis (wtATTR)
By Drug Type:
- Transthyretin Stabilizers
- Nonsteroidal Anti-inflammatory Drugs (NSAID)
- Rnai Therapy
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Eidos Therapeutics
- Ionis Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals
- Prothena Corporation plc
- Intellia Therapeutics, Inc.
- Corino Therapeutics, Inc.

Product Code: CMI4321

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities
- Impact Analysis
- Recent Product Approvals/Launches
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Recent Trends
- Pricing Analysis
- Key Developments
- PEST Analysis
- Porter's Analysis

4. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hereditary Transthyretin Amyloidosis (hATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Wild Type Transthyretin Amyloidosis (wtATTR)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Drug Type, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Transthyretin Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Nonsteroidal Anti-inflammatory Drugs (NSAID)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
RNAi Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

8. Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
North Africa
Central Africa
South Africa